Allergic rhinitis affects a large number of children and exerts a considerable socioeconomic impact. It is underdiagnosed and inadequately treated, which predisposes children to potentially serious comorbidities. Allergic rhinitis symptoms may create nighttime breathing problems and sleep disturbances and have a negative effect on a child's ability to learn in the classroom. Although antihistamines have shown efficacy in relieving many symptoms, they have little effect on nasal congestion. This article summarizes the advantages of intranasal corticosteroids, including their effectiveness against congestion and excellent safety profile. Intranasal corticosteroids with minimal systemic bioavailability provide topical drug delivery that minimizes the potential for systemic side-effects.
Nathan RA, Meltzer EO, Selner JC, Storms W.Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997;99:S808-S814.
2.
European Community RespiratoryHealth Survey.Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS) . Eur Respir J. 1996;9:687-695.
3.
Asher MI, Montefort S., Björkstén B., et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases one and three repeat multicountry cross-sectional surveys: ISAAC Phase Three Study Group. Lancet. 2006;368:733-743.
4.
Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C.A cost of illness study of allergic rhinitis in the United States . J Allergy Clin Immunol. 1997;99: 22-27.
Newacheck PW , Stoddard JJPrevalence and impact of multiple childhood chronic illnesses. J Pediatr. 1994 ;124: 40-48.
7.
Ray NF, Baraniuk JN, Thamer M., et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J Allergy Clin Immunol. 1999;103:401-407.
8.
Fireman P.Therapeutic approaches to allergic rhinitis: treating the child. J Allergy Clin Immunol. 2000;105: S616-S621.
9.
Vuurman Efpm , van Veggel LMA, Uiterwijk MMC, Leutner D., O'Hanlon JFSeasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy. 1993;71:121-126.
10.
International Conference on Allergic Rhinitis in Childhood. Allergic rhinitis in childhood. Allergy. 1999;54(suppl 55): 7-34.
11.
Juniper EF, Guyatt GH, Dolovich J.Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994;93:413-423.
12.
Simons FELearning impairment and allergic rhinitis. Allergy Asthma Proc. 1996;17:185-189.
13.
McLoughlin J., Nall M., Isaacs B., Petrosko J., Karibo J., Lindsey B.The relationship of allergies and allergy treatment to school performance and student behavior . Ann Allergy. 1983;51:506-510.
14.
Arrighi HM, Maier WC, Redding GJ, Morray BH, Llewellyn CEThe impact of allergic rhinitis in Seattle school children [abstract 208] . J Allergy Clin Immunol. 1995;95:192.
15.
Peroni DG, Piacentini GL, Alfonsi L., et al. Rhinitis in pre-school children: prevalence, association with allergic diseases and risk factors. Clin Exp Allergy. 2003;33: 1349-1354.
16.
Storms W., Meltzer EO, Nathan RA, Selner JCAllergic rhinitis: the patient's perspective. J Allergy Clin Immunol. 1997;99:S825-S828.
17.
Leynaert B. , Neukirch F., Demoly P., Bousquet J.Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106:S201-S205.
18.
Wright AL, Holberg CJ, Martinez FD, Halonen M., Morgan W., Taussig LMEpidemiology of physician-diagnosed allergic rhinitis in childhood . Pediatrics. 1994;94:895-901.
19.
Grossman J.One airway, one disease. Chest . 1997;111: 11S-16S.
20.
Meltzer EOTreatment options for the child with allergic rhinitis. Clin Pediatr (Phila). 1998;37:1-10.
21.
Urschitz MS , Guenther A., Eggebrecht E., et al. Snoring, intermittent hypoxia and academic performance in primary school children. Am J Respir Crit Care Med. 2003;168:464-468.
22.
Kaditis AG, Finder J., Alexopoulos EI, et al. Sleep-disordered breathing in 3,680 Greek children. Pediatr Pulmonol. 2004;37:499-509.
23.
Rachelefsky GSNational guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol. 1999;82:296-305.
24.
Bell IR, Jasnoski ML, Kagan J., King DSIs allergic rhinitis more frequent in young adults with extreme shyness? A preliminary survey. Psychosom Med. 1990;52:517-525.
25.
Bender BG, Fischer TJDifferential impact of allergic rhinitis and allergy medications on childhood learning. Pediatr Asthma Allergy Immunol. 1998;12:1-13.
26.
Cohen P., Pine DS, Must A., Kasen S., Brook J.Prospective associations between somatic illness and mental illness from childhood to adulthood. Am J Epidemiol. 1998;147:232-239.
27.
Martin SE, Engleman HM, Deary IJ, Douglas NJThe effect of sleep fragmentation on daytime function. Am J Respir Crit Care Med. 1996;153:1328-1332.
Flemons WW, Tsai W.Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol. 1997;99:S750-S756.
30.
Lavie P., Gertner R., Zomer J., Podoshin L.Breathing disorders in sleep associated with "microarousals" in patients with allergic rhinitis. Acta Otolaryngol. 1981;92:529-533.
31.
McNicholas WT, Tarlo S., Cole P., et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis . 1982;126:625-628.
32.
Fisher L., Ghaffari G., Davies M., Craig T.Effects of poor sleep in allergic rhinitis. Curr Opin Allergy Clin Immunol. 2005;5:11-16.
33.
Papsidero M.The role of nasal obstruction in obstructive sleep apnea syndrome. Ear Nose Throat J. 1993;72:82-84.
34.
Young T., Finn L., Kim H.; University of Wisconsin Sleep and Respiratory Research Group.Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol. 1997;99:S757-S762.
35.
Craig TJ, Teets S., Lehman EB, Chinchilli VM, Zwillich C.Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids . J Allergy Clin Immunol. 1998;101:633-637.
36.
Zwillich CW, Pickett C., Hanson FN, Weil JVDisturbed sleep and prolonged apneas during nasal obstruction in normal men . Am Rev Respir Dis. 1981;124:158-160.
37.
Craig TJ, Hanks CD, Fisher LHHow do topical nasal corticosteroids improve sleep and daytime somnolence in allergic rhinitis? J Allergy Clin Immunol. 2005;116: 1264-1266.
38.
Reinberg A. , Gervais P., Levi F., Smolensky M., Del Cerro L., Ugolini C.Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods. J Allergy Clin Immunol. 1988;81:51-62.
39.
Rundcrantz H.Postural variations of nasal patency. Acta Otolaryngol. 1969;68:435-443.
40.
Santos CB, Pratt EL, Hanks C., McCann J., Craig TJAllergic rhinitis and its effect on sleep, fatigue, and daytime somnolence . Ann Allergy Asthma Immunol. 2006; 97:579-587.
41.
Shedden A.Impact of nasal congestion on quality of life and work productivity in allergic rhinitis: findings from a large online survey. Treat Resp Med. 2005; 4:439-446.
42.
Mansfield LE , Diaz G., Posey CR, Flores-Neder J.Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann Allergy Asthma Immunol. 2004 ;92: 240-244.
43.
American Thoracic Society.Cardiorespiratory sleep studies in children: establishment of normative data and polysomnographic predictors of morbidity . Am J Respir Crit Care Med. 1999;160:1381-1387.
44.
Fredriksen K., Rhodes J., Reddy R., Way N.Sleepless in Chicago: tracking the effects of adolescent sleep loss during the middle school years . Child Dev. 2004;75:84-95.
45.
Blaiss M.Current concepts and therapeutic strategies for allergic rhinitis in school-age children. Clin Ther. 2004;26:1876-1889.
46.
Scadding GKCorticosteroids in the treatment of pediatric allergic rhinitis. J Allergy Clin Immunol. 2001;108: S59-S64.
47.
Bousquet J. , Lockey R., Malling H-J ; the WHO Panel Members. Allergen immunotherapy: therapeutic vaccines for allergic diseases: a WHO position paper. J Allergy Clin Immunol. 1998 ;102:558-563.
48.
Bousquet J. , van Cauwenberge P., Khaltaev N; the ARIA Workshop Group of the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol. 2001;108(suppl 5):S147-S334.
49.
Tashiro M., Mochizuki H., Iwabuchi K., et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci. 2002;72:409-414.
50.
Krouse HJ, Davis JE, Krouse JHImmune mediators in allergic rhinitis and sleep. Otolaryngol Head Neck Surg. 2002;126:607-613.
51.
Ferguson BJInfluences of allergic rhinitis on sleep. Otolaryngol Head Neck Surg. 2004;130:617-629.
52.
Passalacqua G., Bousquet J., Bachert C., et al. The clinical safety of H1-receptor antagonists: an EAACI position paper. Allergy. 1996;51:666-675.
53.
Ng KH, Chong D., Wong CK, et al. Central nervous system side effects of first- and second-generation antihistamines in school children with perennial allergic rhinitis: a randomized, double-blind, placebo-controlled comparative study. Pediatrics . 2004;113:e116-e121.
54.
Saengpanich S., Assanasen P., de Tineo M., Haney L., Naclerio RM, Baroody FMEffects of intranasal azelastine on the response to nasal allergen challenge. Laryngoscope . 2002;112:47-52.
55.
Golden S., Teets SJ, Lehman EB, et al. Effect of topical nasal azelastine on the symptoms of rhinitis, sleep, and daytime somnolence in perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2000;85:53-57.
Banov CH, Lieberman P.; the Vasomotor Rhinitis Study Group. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol. 2001;86:28-35.
58.
American Academy of Allergy Asthma & Immunology.The allergy report, volume 2: diseases of the atopic diathesis . http://www.aaaai.org/ar/volume2.pdf. Accessed April 2, 2007.
59.
McLean HA, Urton AM, Driver HS, et al. Effect of treating severe nasal obstruction on the severity of obstructive sleep apnea. Eur Respir J. 2005;25:521-527.
60.
Milgrom H., Biondi R., Georgitis JW, et al. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol. 1999;83:105-111.
61.
Meltzer EO, Philip G., Weinstein SF, et al. Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis. Am J Rhinol. 2005;19:591-598.
62.
Moinuddin R. , deTineo M., Maleckar B., Naclerio RM, Baroody FMComparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis . Ann Allergy Asthma Immunol. 2004;92:73-79.
63.
Patel P., Philip G., Yang W., et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2005;95:551-557.
64.
van Cauwenberge P., Bachert C., Passalacqua G., et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116-134.
65.
Mintz M., Garcia J., Diener P., Liao Y., Dupclay L., Georges G.Triamcinolone acetonide aqueous nasal spray improves nocturnal rhinitis-related quality of life in patients treated in a primary care setting: the Quality of Sleep in Allergic Rhinitis Study. Ann Allergy Asthma Immunol . 2004;92:255-261.
66.
Hughes K., Glass C., Ripchinski M., et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis . Allergy. 2003;58:380-385.
67.
Potter PC, Van Niekerk CH, Schoeman HSEffects of triamcinolone on quality of life in patients with persistent allergic rhinitis. Ann Allergy Asthma Immunol. 2003 ;91: 368-374.
68.
Dykewicz MS , Fineman S.Executive summary of Joint Task Force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol. 1998; 81:463-468.
69.
Kaari J.The role of intranasal corticosteroids in the management of pediatric allergic rhinitis. Clin Pediatr (Phila). 2006;45:697-704.
70.
Galant SP, Wilkinson R.Clinical prescribing of allergic medication in the preschool and young school-age child: what are the options? BioDrugs. 2001 ;15:453-463.
71.
Hagemann TMPediatric allergic rhinitis drug therapy. J Pediatr Health Care. 2005;19:238-244.
72.
Lai L., Casale TB, Stokes J.Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am. 2005;25:283-299.
73.
Ngamphaiboon J., Thepchatri A., Chatchatee P., Chumdermpadetsuk S.Fluticasone propionate aqueous nasal spray treatment for perennial allergic rhinitis in children . Ann Allergy Asthma Immunol. 1997 ;78:479-484.
74.
Welch MJ, Bronsky EA, Grossman J., et al. Clinical evaluation of triamcinolone acetonide nasal aerosol in children with perennial allergic rhinitis. Ann Allergy . 1991;67:493-498.
75.
Fokkens WJ, Cserháti E., Lopes dos Santos JM, et al. Budesonide aqueous nasal spray is an effective treatment in children with perennial allergic rhinitis, with an onset of action within 12 hours. Ann Allergy Asthma Immunol. 2002 ;89:279-284.
76.
Bender BG, Milgrom H.Comparison of the effects of fluticasone propionate aqueous nasal spray and loratadine on daytime alertness and performance in children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2004;92:344-349.
77.
Meltzer EO, Berger WE, Berkowitz RB, et al. A dose-ranging study of mometasone furoate aqueous nasal spray in children with seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:107-114.
78.
Wolthers OD , Pedersen S.Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids . Acta Paediatr. 1993;82:635-640.
79.
Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105:e23.
80.
Rachelefsky GS, Chervinsky P., Meltzer EO, et al. An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray (Vancenase AQ [VNS]) on long-term growth in children [abstract 979]. J Allergy Clin Immunol. 1998;101:S236.
81.
Gillman SA, Anolik R., Schenkel E., et al. One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatr. 2002;41:333-340.
82.
Piacentini GL, Sette L., Peroni DG, et al. Double-blind evaluation of effectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children . Allergy. 1990;45:612-616.
83.
Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc. 2002;23:407-413.
84.
Agertoft L. , Pedersen S.Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide . J Allergy Clin Immunol. 1999;104:948-952.
85.
Schenkel EJ , Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis following 1 year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000 ;105:e22.
Brannan MD, Herron JM, Reidenberg P., Affrime MBLack of HPA axis suppression following 36 days of intranasal mometasone furoate [abstract P207]. Ann Allergy Asthma Immunol. 1997;78:154.
88.
Brannan MD, Seiberling M., Cutler DL, Cuss FM, Affrime MBLack of systemic activity with intranasal mometasone furoate [abstract 62] . J Allergy Clin Immunol. 1996;97(suppl):S198.
89.
Wilson AM, Sims EJ, McFarlane LC, Lipworth BJEffects of intranasal corticosteroids on adrenal, bone, and blood markers of systemic activity in allergic rhinitis. J Allergy Clin Immunol.1998;102:598-604.
90.
Lee DKC , Robb FM, Sims EJ, Currie GP, McFarlane LC, Lipworth BJSystemic bioactivity of intranasal triamcinolone and mometasone in perennial allergic rhinitis . Br J Clin Pharmacol . 2003;55:310-313.
91.
Kim KT, Rabinovitch N., Uryniak T., Simpson B., O'Dowd L., Casty F.Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2004; 93:61-67.
92.
Mygind N., Clark TJH.Safety and topical side-effects. In: Mygind N, Clark TJH, eds. Topical Steroid Treatment for Asthma and Rhinitis. London , England: Baillière Tindall;1980 :171-179.
93.
Fireman P.A comparison of intranasal beclomethasone dipropionate with other agents in the treatment of rhinitis: a review of the published clinical experience . Today's Therapy Trends. 1991;9:21-34.
94.
Rao R., Gregson RK, Jones AC, Miles EA, Campbell MJ, Warner JOSystemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur Respir J. 1999;13:87-94.
95.
Skoner DP, Gentile D., Angelini B., Kane R., Birdsall D., Banerji D.The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003 ;90:56-62.
96.
Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003;112:96-100.
97.
Nayak AS, Ellis MH, Gross GN, et al. The effects of triamcinolone acetonide aqueous nasal spray on adrenocortical function in children with allergic rhinitis. J Allergy Clin Immunol. 1998;101:157-162.
98.
Brannan MD, Herron JM, Affrime MBSafety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther. 1997;19:1330-1339.
99.
Onrust SV, Lamb HMMometasone furoate: a review of its intranasal use in allergic rhinitis. Drugs. 1998;56: 725-745.
100.
Chrousos GP , Ghaly L., Shedden A., Iezzoni DG, Harris AGEffects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest. 2005;128:70-77.
101.
Cutler DL, Banfield C., Affrime MBSafety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol. 2006;19: 146-153.
